We would like to happily announce that MultiplexDX was awarded by an IPA4SME grant. As a three-time “Seal of Excellence” holder, we met all the criteria established by the EU commission to be selected for this grant. IPA4SME provides financial and expert support for intellectual property (IP) valorisation and protection services to SMEs that have received a Seal of Excellence from the H2020 SME Instrument program.
Dr. Peter Killian (COO of MultiplexDX) answered our questions regarding the received grant:
What does it mean for MultiplexDX to be selected for this IPA4SME grant?
Being awarded this grant by the European Commission in fierce competition with other SMEs from all around Europe confirms that MultiplexDX belongs to an elite group of the most innovative SMEs in Europe.
How are you going to use/spend this grant and for what is it helpful?
This grant is intended for partial reimbursement of fees for filing a European patent application as well as related attorney fees. We want to protect our IP on multiplexing technology therefore this grant is a perfect fit.
The protection of IP is crucial for promoting innovation and boosting the competitiveness of European SME grants. Therefore, IPA4SME offers several services like IP Pre-diagnostics, IP Protection Co-financing, EPO (European Patent Office) fee reimbursement and IP attorney fee reimbursement. The grant provides an analysis of SMEs’ existing technology from a qualified expert and knowledge assets along with a customized IP business strategy. IPA4SME aims to foster an environment in which creativity and innovation can flourish.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.